OECD Home › Health › Publications & Documents › Best Practices / Guidelines
Best Practices / Guidelines
English, PDF, 2,030kb
Health financing systems have undergone considerable change over recent decades. Better resource management has led countries to introduce new financial mechanisms and innovative institutional arrangements. The SHA 2011 Financing Framework mirrors such changes, enabling health accountants and analysts to obtain a clear picture of health care financing and provide policy-relevant information concerning the structure and flows of funds.
English, PDF, 162kb
OECD Health Data 2012: How to create tables in OECD.Stat
English, , 429kb
This guide comprises eight key points for planning public engagement activities. It contains a set of questions to help policy makers develop a plan from start to finish, as well as practical case studies from countries that have used the guide in their communication activities.
The OECD has launched a project on variations in medical practice, as reducing unwarranted variations in medical practice may contribute to increasing quality, efficiency and equity in health care delivery.
The Recommendation seeks to assist both OECD member and non-member countries in the development of appropriate sustainability assessment methodologies for bio-based products.
English, , 287kb
The aim of these guidelines is to propose a harmonised approach for the collection and analysis of biotechnology research and development (R&D) statistics in the government and higher education sectors.
The ability to effectively use these vast amounts of knowledge will depend in part on the bringing together of different strands of information, data and biological materials within human biobanks and genetic research databases (HBGRDs).
English, , 218kb
Background document for the OECD-Eurostat-WHO SHA Data Questionnaire.
Genetics is playing an increasingly important role in health care. New technical advances and information deriving from human genome research are changing health care practices and the economics of healthcare provision.
This report presents the outcome of discussions held by the OECD member countries, together with a number of key partner countries, under the auspices of an expert Task Force established by the OECD Working Party on Biotechnology.